Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Rosario, M. H., . . . Arteaga, C. L. (2020). Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers. Cancer Cell.
Stile di citazione ChicagoSudhan, Dhivya R., et al. "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-mutant Cancers." Cancer Cell 2020.
Citazione MLASudhan, Dhivya R., et al. "Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-mutant Cancers." Cancer Cell 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.